Artelo Biosciences Inc. (ARTL)
0.95
-0.02 (-2.06%)
At close: Apr 17, 2025, 3:53 PM
0.92
-3.81%
After-hours: Apr 17, 2025, 07:56 PM EDT
-2.06% (1D)
| Bid | 0.89 |
| Market Cap | 3.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.29M |
| EPS (ttm) | -3.05 |
| PE Ratio (ttm) | -0.31 |
| Forward PE | -1.77 |
| Analyst | Buy |
| Ask | 0.95 |
| Volume | 124,614 |
| Avg. Volume (20D) | 404,774 |
| Open | 0.91 |
| Previous Close | 0.97 |
| Day's Range | 0.88 - 0.96 |
| 52-Week Range | 0.82 - 1.59 |
| Beta | 1.17 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2019
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ARTL
Website https://www.artelobio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ARTL stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 529.06% from the latest price.
Stock Forecasts9 months ago
+3.1%
Artelo Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
